Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021Business Wire • 10/19/21
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying EnzymesBusiness Wire • 10/14/21
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's LymphomaBusiness Wire • 10/14/21
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO PresentationBenzinga • 09/20/21
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021Business Wire • 09/20/21
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021Business Wire • 09/18/21
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 09/17/21
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior SurgeryBenzinga • 09/16/21
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021Business Wire • 09/16/21
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in SeptemberBusiness Wire • 09/01/21
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell CarcinomaBusiness Wire • 08/25/21
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in OncologyBusiness Wire • 08/16/21